Dermatology biotech Dermira files for a $75 million IPO

Dermira, a late-stage biotech developing treatments for psoriasis and other skin conditions, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. 

The Redwood City, CA-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol DERM. Rhythm Pharmaceuticals initially filed confidentially on June 26, 2014. Citi and Leerink are the joint bookrunners on the deal. No pricing terms were disclosed.